Abstract: Nanoparticles comprising at least three polymers, selected independently of one another from the list comprising PLGA, PLA, TPGS, TPGS-750M, PVA, LAEOLA/PLA-PEO-PLA, and also at least one active ingredient, selected from the list comprising paclitaxel, docetaxel and SB-T-1214. The particles have a core-shell structure, the core containing the at least one active ingredient and at least two polymers, the polymers being selected independently of one another from the list comprising RG502H, RG504, PLA, LAEOLA/PLA-PEO-PLA, TPGS and TPGS-750M, the shell containing PVA and/or TPGS. The nanoparticles are nebulizable.

Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is patient-friendly, effective, and well tolerated. Bolus inhalation may, for example, be achieved using an efficient nebuliser based on the vibrating mesh technology.

Abstract: The invention relates to liposomes for pulmonary application, advantageously comprising at least one first and at least one second phospholipid, cholesterol, and at least one active substance and/or colorant, wherein the first phospholipid is a phosphatidylcholine, preferably DSPC, and the second phospholipid is a phosphatidylcholine or an ethanolamine, preferably selected from the group DMPC, DPPC, DPPE. It is thereby advantageous if the first and the second phospholipid are present at a molar ratio of 0.5:1 to 10:1, preferably at a ratio of 6:1 to 2:1, in particular preferably at a ratio of 3:1. It is further advantageous if the molar ratio between phospholipids and cholesterol is between 10:1 and 1:1, preferably between 6:1 and 3:1, in particular preferably 4:1. The second phospholipid is further preferably DMPC or DPPE, in particular preferably DPPE. The size of the liposomes is advantageously between 0.05 ?m and 5 ?m, preferably between 0.2 ?m and 2.

Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is patient-friendly, effective, and well tolerated. Bolus inhalation may, for example, be achieved using an efficient nebuliser based on the vibrating mesh technology.

Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. The administration is by inhalation over a short period of time, which is patient-friendly, effective, and well tolerated. Inhalation may, for example, be achieved using an efficient nebulizer based on the vibrating mesh technology.

Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. The administration is by inhalation over a short period of time, which is patient-friendly, effective, and well tolerated. Inhalation may, for example, be achieved using an efficient nebulizer based on the vibrating mesh technology.

Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is patient-friendly, effective, and well tolerated. Bolus inhalation may, for example, be achieved using an efficient nebuliser based on the vibrating mesh technology.

Abstract: The present invention provides biocompatible nano-polymer particles which are composed of a biocompatible polymer, a stabilizer and an active agent for the treatment of pulmonary hypertension or erectile dysfunction and which can be used to produce a pharmaceutical preparation for the treatment of pulmonary hypertension or erectile dysfunction. Biocompatible nano-polymer particles of this invention have a diameter ranging from 10 nm to 10 ?m auf, a stabilizing layer thickness between 0 and 50 nm, contain between 0 and 50% of an active agent for the treatment of pulmonary hypertension or erectile dysfunction, are nebulizable and continuously release the active agent over a period of up to 48 hours. Biocompatible nano-polymer particles of this invention can be synthesized for example using the emulsion technique known to the expert with subsequent solvent evaporation or via spray drying.

Abstract: The present invention provides stabilizers for the coating of biocompatible nano- and microparticles which prevent aggregation of the particles during preparation, storage as well as before and after nebulization and which are suitable to be utilized for the manufacture of a pharmaceutical preparation for pulmonary application. Biocompatible nano- and microparticles of this invention have a stabilizer layer thickness ranging from 1 to 200 nm and contain an active substance. Said biocompatible nano- and microparticles of this invention can be synthesized for example using the emulsion method known to the expert with subsequent coating by mixing of uncoated particles with the stabilizer, by chemical vapor deposition, by spraying or by covalent attachment.

Abstract: The present invention discloses a method to prepare specific liposomal formulations for the pulmonary application of therapeutic substances. The liposomal components, DPPC and cholesterol at a molar ratio of 7:3 and 7:4, respectively, are combined with the non-toxic excipients, sphingomyelin, dimyristoylphophatidylcholine and/or polyethylene glycol, to prepare liposomes that are stabile during nebulization with commercially available nebulizers and exhibit sustained release kinetics of encapsulated drug substances.

Abstract: The present invention provides nano-, meso- and micro-polymer particles which are able to bind pathogenic proteins penetrating into the lining layer of the lung. Known pathogenic proteins in the pulmonary lining layer are negatively charged. These proteins damage the pulmonary surfactant system which is essential to maintain a low surface tension in the lung and thus a functional respiration. Polymer particles of this invention have a diameter between 20 nm and 10 ?m, are water-insoluble, have a positive surface charge and a low surface hydrophobicity. The isoelectric point of said particles is greater than 5 to that said particles are present in the lining layer of the lung as positively charged particles, and at the same time higher than the isoelectric point of the pathogenic protein to be bound. Polymer particles of this invention can for example be prepared using the precipitation or emulsion method.

Abstract: The invention relates to liposomes for pulmonary application, advantageously comprising at least one first and at least one second phospholipid, cholesterol, and at least one active substance and/or colorant, wherein the first phospholipid is a phosphatidylcholine, preferably DSPC, and the second phospholipid is a phosphatidylcholine or an ethanolamine, preferably selected from the group DMPC, DPPC, DPPE. It is thereby advantageous if the first and the second phospholipid are present at a molar ratio of 0.5:1 to 10:1, preferably at a ratio of 6:1 to 2:1, in particular preferably at a ratio of 3:1. It is further advantageous if the molar ratio between phospholipids and cholesterol is between 10:1 and 1:1, preferably between 6:1 and 3:1, in particular preferably 4:1. The second phospholipid is further preferably DMPC or DPPE, in particular preferably DPPE. The size of the liposomes is advantageously between 0.05 ?m and 5 ?m, preferably between 0.2 ?m and 2.

Abstract: The invention relates to composite materials comprising polymer nanofibers and polymer nanoparticles, wherein at least one of the two polymer materials is loaded with a substance selected from therapeutic and diagnostic agents. Fibers and nanoparticles can comprise identical or different polymers; the polymer materials are, however, biocompatible in every case. Therapeutic and diagnostic agents can be hydrophilic or lipophilic and the two polymer materials likewise. The at least one polymer material and the substance with which said material is loaded are either both hydrophilic or both lipophilic. The polymer nanoparticles of the composite materials have a diameter of 10 nm to 600 nm. The polymer fibers have diameters of 10 nm to 50 ?m and lengths of 1 ?m to several meters. The invention further relates to a method for producing said composite materials.

Abstract: The present invention related to a non-viral vector system for the delivery of nucleic acids which is modified on the basis of polyethylene imine (PEI) with polyethylene glycol (PEG) and which contains a peptide sequence with PTD/CPP-functionality. This vector system is used as gene transfer system for the epithelial cells of the bronchial tubes and alveoli of the lung. The system is highly stable, protects the DNA in the pulmonary environment, has a low zeta-potential and a low aggregation tendency in a medium with a high ionic strength. Furthermore, it is characterized by a low in vitro and in vivo cytotoxicity and allows for a very high transfection efficiency. The vector system according to the present invention is used for a transfection by inhalation in local pulmonary therapy.

Abstract: The invention relates to novel anisometric mesoparticles and nanoparticles in the form of anisometric mesofibers/nanofibers, mesopipes/nanopipes, mesobands/nanobands, mesocables/nanocables, and the curved and branched or superimposed variations thereof as well as a novel method for the production thereof. The invention particularly relates to anisometric mesoparticles and nanoparticles which have an aerodynamic diameter <5 ?m, the production thereof, loading thereof with active substances if the same cannot directly be utilized as an active substance, and the use thereof especially for producing medicaments against lung diseases or systemic diseases in humans and animals if the particles cannot directly be utilized as medicaments without carriers.

Abstract: The invention relates to an equine inhalation mask, comprising at least one valveless combined inhalation and exhalation conduit, into which inhalant sources comprising respiration control elements and an energy supply that does not require supply lines are interchangeably integrated. A filter system is mounted on the outer end of the inhalation and exhalation conduit facing away from the head of the horse. Said system and the fact that the mask is effectively sealed when on the head of the horse prevent any escape of the aerosol into the environment, thus permitting a reliable inhalation therapy lasting several minutes under normal respiratory conditions.

Abstract: The invention concerns a compound formed from a biologically degradable, water-soluble comb polymer based on a polyol backbone with side chains carrying amino groups, and, as a stabilizer, at least one negatively charged organic base, which can be a Lewis or Bronsted base, or its corresponding acid, which can be a Lewis or Bronsted acid, wherein the acid groups of the stabilizers are available in excess or deficiency in relation to the primary, secondary or tertiary amino groups or the basic groups are available in excess or deficiency in relation to the quaternary amino groups of the comb polymers, so that the colloidal particles feature a positive or negative zeta potential. Such colloidal particles are particularly suitable for pulmonary application of acidic or negatively charged pharmaceutically active ingredients.

Abstract: The present invention discloses a method to prepare specific liposomal formulations for the pulmonary application of therapeutic substances. The liposomal components, DPPC and cholesterol at a molar ratio of 7:3 and 7:4, respectively, are combined with the non-toxic excipients, sphingomyelin, dimyristoylphophatidylcholine and/or polyethylene glycol, to prepare liposomes that are stabile during nebulization with commercially available nebulizers and exhibit sustained release kinetics of encapsulated drug substances.

Abstract: The invention relates to an equine inhalation mask, comprising at least one valveless combined inhalation and exhalation conduit, into which inhalant sources comprising respiration control elements and an energy supply that does not require supply lines are interchangeably integrated. A filter system is mounted on the outer end of the inhalation and exhalation conduit facing away from the head of the horse. Said system and the fact that the mask is effectively sealed when on the head of the horse prevent any escape of the aerosol into the environment, thus permitting a reliable inhalation therapy lasting several minutes under normal respiratory conditions.

Abstract: A combination mouthpiece for inhalation therapy devices, having a body (1) defining an aerosol duct (2) through which, in use, a stream of air carrying an aerosolized drug is supplied to a patient during inspiration, an inlet hole (4) through the body for receiving in a releasable and secure manner an oxygen tube adapter (5), characterised by at least one partition (6) within the body (1) defining at least one oxygen duct (3), the oxygen duct being in a form such that it extends generally parallel with the aerosol duct (2) and has a flow cross-section sized in order to guide a suitably large oxygen stream from the oxygen tube adapter (5) through the inlet hole (4) to the patient.